1-20 of 79 results for subject:Screening
Librarians' tools
- Search time
- 0.249 seconds
- Solr query time
- 0.016 seconds
- Search query
- subject:Screening
- We searched for
- subject_t:Screening OR subject_ses:92923
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what estimate she has made of the number of people aged 75 and over who have phoned the free bowel cancer screening helpline in each of the last three years.
To ask the Secretary of State for Health and Social Care, what estimate she has made of the number of people aged 75 and over who have phoned the free bowel cancer screening helpline in each of the last three years.
Further to the answer provided to the Hon Member on 22 January 2026 which covers years 2023 and 2024 in response to Question 106495, 123,479 people aged 75 years old and over requested a bowel cancer test kit in the calendar year 2025. Of these, 97% completed the screening test.
That this House remembers Teddy Johnston of Portadown, who tragically lost his life to metachromatic leukodystrophy (MLD); commends the courage and determination of his parents, Marvin and Gemma Johnston, in campaigning for change; recognises that a commissioned treatment for MLD already exists in the UK and is most effective when administered before symptoms appear; notes that early diagnosis through newborn heel-prick screening is essential to ensure children can access that treatment; further notes that the UK has fallen behind many comparable countries in expanding newborn blood spot screening, despite the availability of life-changing treatments for a growing number of rare conditions; welcomes the Prime Minister’s commitment to review the recommendation of the UK National Screening Committee in relation to MLD screening; and calls on the Government to act urgently to include MLD in the newborn heel-prick screening programme so that Teddy’s legacy is one of hope and that no other family experiences a preventable loss.
That this House remembers Teddy Johnston of Portadown, who tragically lost his life to metachromatic leukodystrophy (MLD); commends the courage and determination of his parents, Marvin and Gemma Johnston, in campaigning for change; recognises that a commissioned treatment for MLD already exists in the UK and is most effective when...
That this House expresses profound concern at the decision by the Northern Ireland Health minister not to establish a statutory public inquiry into the Northern Ireland cervical screening scandal involving the Southern Health and Social Care Trust; notes that approximately 17,500 women had smear test results reviewed following serious failings in cervical screening services over a period spanning more than a decade; further notes that a number of women developed cervical cancer following misread smear tests and that two young mothers, Lynsey Courtney and Erin Harbinson, tragically lost their lives; recognises the tireless campaigning work of the Ladies with Letters group in seeking truth, transparency and accountability; believes that only a full statutory public inquiry established under the Inquiries Act 2005 would possess the necessary powers to compel witnesses and documentation, hold hearings in public and fully establish the extent of systemic failings; regrets that victims and families continue to feel denied full answers and justice; and calls on the Government and all relevant authorities to support the establishment of a comprehensive public inquiry capable of restoring public confidence in cervical screening services and ensuring lessons are fully learned for the future.
That this House expresses profound concern at the decision by the Northern Ireland Health minister not to establish a statutory public inquiry into the Northern Ireland cervical screening scandal involving the Southern Health and Social Care Trust; notes that approximately 17,500 women had smear test results reviewed following serious failings...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 January 2026 to Question 106495, what assessment has been made of the reasons for the 25% reduction in the numbers of those aged 75 and over self referring for bowel cancer screening between...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 January 2026 to Question 106495, what assessment has been made of the reasons for the 25% reduction in the numbers of those aged 75 and over self referring for bowel cancer screening between...
Improving cancer services is a priority for the Government. We will get the National Health Service diagnosing cancer earlier and treating it faster so that more patients survive, and we will improve patients’ experience across the system.
The bowel cancer screening programme primarily focuses on uptake and coverage of those eligible for screening, those aged 50 to 74 years old, and how these individuals progress through the pathway for additional diagnostic tests where required. As those over 75 years old self-referring fall outside the primary cohort no analysis has been made of the fluctuations in numbers.
Over 75s can still ask for a kit every two years by phoning the free bowel cancer screening helpline. Anyone experiencing symptoms is encouraged to seek medical advice immediately.
To ask the Secretary of State for Health and Social Care, how many people over 75 self referred for bowel cancer screening in (a) 2023 and (b) 2024.
To ask the Secretary of State for Health and Social Care, how many people over 75 self referred for bowel cancer screening in (a) 2023 and (b) 2024.
The NHS Bowel Cancer Screening Programme plays a vital role in the Government's ambition to change the National Health Service so that it diagnoses earlier and treats faster.
Although people aged 75 years old and over are not routinely invited, they can self-refer and ask for a bowel cancer screening kit every two years by phoning the free bowel cancer screening helpline.
In 2023, 132,425 people aged 75 years old and over requested a test kit. Of these, 99% completed the screening test.
In 2024, 99,516 people aged 75 years old and over requested a test kit, with 98% completing the screening test.
To ask the Secretary of State for Health and Social Care, when does he expect to receive the outcome of the Prostate Cancer UK-led Transform screening trial.
To ask the Secretary of State for Health and Social Care, when does he expect to receive the outcome of the Prostate Cancer UK-led Transform screening trial.
The Government is partnering with Prostate Cancer UK (PCUK) on the £42 million TRANSFORM screening trial to find the best way to screen men for prostate cancer to find it before it becomes advanced and harder to treat. PCUK is managing the award on behalf of the funders, with the Government contributing £16 million through the National Institute for Health and Care Research (NIHR).
In November 2025, the TRANSFORM trial began recruitment as part of the initial 16,000 men taking part in stage one, from 2025 to 2027, which will test new techniques against the current National Health Service diagnostic pathway. Although the TRANSFORM trial will run for over a decade, there will be multiple points during the trial where new evidence will be generated, with stage 1 due to end in April 2027.
The UK National Screening Committee are working closely with the TRANSFORM trial team and will assess new evidence as it becomes available. This will ensure that prostate cancer policy is kept at the forefront of the Government’s cancer agenda.
The NIHR continues to encourage and welcome applications for research into any aspect of human health and care, including prostate cancer.
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that men at highest risk of prostate cancer take part in screening trials.
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that men at highest risk of prostate cancer take part in screening trials.
The Government and Prostate Cancer UK (PCUK) have partnered together on the £42 million TRANSFORM screening trial to find the best way to screen men for prostate cancer, to find it before it becomes advanced and harder to treat. PCUK is leading the development of the trial, with the Government contributing £16 million through the National Institute for Health and Care Research.
The TRANSFORM trial will aim to address some of the inequalities that exist in prostate cancer diagnosis. For example, one in four black men will develop prostate cancer, double the risk of other men, and often at a younger age. The trial will ensure that at least 10% of the men who are invited to participate in the trial are black.
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the reduction in the qualifying age for bowel cancer screening on detection rates in the past five years.
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the reduction in the qualifying age for bowel cancer screening on detection rates in the past five years.
The final roll out of this policy only concluded in April 2025. As such, NHS England has not yet made any formal assessment of the impact of lowering the age for bowel cancer screening down to 50 on detection rates.
However, when making the recommendation to extend the screening age, from 60- to 74- year olds to 50- to 74- year olds, and to replace the faecal occult blood test with the faecal immunochemical test at the current test sensitivity threshold of 120 micrograms of haemoglobin per gram of faeces, these two activities combined were estimated to nearly double the number of colorectal cancer incidences detected and mortality reduced.
That this House acknowledges that International Men’s Day, observed globally each year on 19 November, highlights issues affecting men, including prostate cancer, which is the most common cancer in men, with more than 56,000 men diagnosed and 12,000 dying each year in the UK; notes with concern that Black men face double the risk of developing prostate cancer and are twice as likely to die from it compared to their White counterparts; emphasises that too many men die from prostate cancer due to late diagnosis and that early detection saves lives; recognises the importance of continued investment to build the evidence for a safe and accurate screening programme, including Prostate Cancer UK’s TRANSFORM trial in partnership with government; highlights that targeted screening using prostate-specific antigen blood tests for early detection in primary care, particularly for Black men over 45 and men with a family history, is essential to save lives in highest-risk groups; calls on the Government to review the Prostate Cancer Risk Management Programme in line with the National Screening Committee’s recommendation, irrespective of the Committee’s conclusion; and urges the forthcoming National Cancer Plan for England to prioritise early detection of prostate cancer to reduce health inequalities and improve outcomes for all men at risk.
That this House acknowledges that International Men’s Day, observed globally each year on 19 November, highlights issues affecting men, including prostate cancer, which is the most common cancer in men, with more than 56,000 men diagnosed and 12,000 dying each year in the UK; notes with concern that Black men...
To ask the Secretary of State for Health and Social Care, how many and what proportion of people aged 75 years and over have requested a bowel screening kit by phoning the free bowel cancer screening helpline in the last two years.
To ask the Secretary of State for Health and Social Care, how many and what proportion of people aged 75 years and over have requested a bowel screening kit by phoning the free bowel cancer screening helpline in the last two years.
The National Health Service bowel cancer screening programme’s published data for 1 April 2022 to 31 March 2024 shows that 396,325 people self-referred or opted back into the programme within the year. This includes ‘over-age self-referrals’, those aged 75 years old and over who are not invited routinely, and also ‘late responder self-referrals’ who have not responded to the initial invitation but have later chosen to participate. This data cannot be disaggregated into each of the categories listed. This data is provided in the Bowel cancer screening standards data report 2022/23 and the Bowel cancer screening standards data report 2023/24, which are available, respectively, at the following two links:
Additional unpublished data available to the programme shows that for this time period, from 1 April 2022 to 31 March 2024, 224,665 requests were made for self-referrals from individuals who are aged 75 years old and over. We are unable to identify if all of these requests were made via the bowel screening helpline. The total number of people aged 75 years old and over is 5,736,072, sourced from the Patients Registered at a GP Practice, October 2025 dataset, which is available at the following link:
I congratulate the hon. Lady on securing the debate. She is outlining very clearly the importance of the issue. It is vital that people are aware of it. Does she agree that if we do not deal with the issue, the NHS waiting lists over the coming years will be...
I congratulate the hon. Lady on securing the debate. She is outlining very clearly the importance of the issue. It is vital that people are aware of it. Does she agree that if we do not deal with the issue, the NHS waiting lists over the coming years will be...
To ask the Secretary of State for Health and Social Care, whether the outcome of the Prostate Cancer UK-led TRANSFORM screening trial will be shared with Health Departments in each of the devolved institutions.
To ask the Secretary of State for Health and Social Care, whether the outcome of the Prostate Cancer UK-led TRANSFORM screening trial will be shared with Health Departments in each of the devolved institutions.
The TRANSFORM screening trial, funded in partnership with Prostate Cancer UK, is investigating new prostate cancer screening methods. This national randomised control trial will provide data to policymakers for a decision on recommending prostate cancer screening. Results will be shared with the UK National Screening Committee, representing all four nations.
That this House marks Sarcoma Awareness Month 2025, celebrated in July, which raises awareness about Sarcoma, a rare type of cancer that develops in soft bones and tissues; notes the theme of this year's awareness is early diagnosis and educating the public on the most common of symptoms and the life of people dealing with the impacts it can have; highlights that approximately 5,300 people are diagnosed with Sarcoma in the UK each year, making up 2% of all cancers diagnosed in the UK each year; underlines that Sarcoma is often referred to as the loneliest cancer because it has over 100 different subtypes and people with it often never meet someone with the same subtype; thanks Sarcoma UK and other charities for their work in ensuring support is available for people diagnosed with sarcoma; and encourages the Government to ensure that it delivers high-quality care for people with sarcoma in the future.
That this House marks Sarcoma Awareness Month 2025, celebrated in July, which raises awareness about Sarcoma, a rare type of cancer that develops in soft bones and tissues; notes the theme of this year's awareness is early diagnosis and educating the public on the most common of symptoms and the...
To ask the Secretary of State for Health and Social Care, when he expects the Prostate Cancer UK-led Transform screening trial to reach any conclusions on future detection of the condition.
To ask the Secretary of State for Health and Social Care, when he expects the Prostate Cancer UK-led Transform screening trial to reach any conclusions on future detection of the condition.
Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year in research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer as the largest area of spend, at over £133 million in 2023/24, reflecting its high priority. The NIHR funds research and research infrastructure, which supports patients and the public to participate in high-quality research, including clinical research on prostate cancer.
These investments are pivotal towards efforts to improve cancer prevention, treatment, and outcomes. The TRANSFORM trial is an important example of this. On 19 November, the Government and Prostate Cancer UK (PCUK) announced the £42 million TRANSFORM screening trial, to find the best way to screen men for prostate cancer in order to find it before it becomes advanced and harder to treat. PCUK is leading the development of the trial, with the Government contributing £16 million through the Department.
The first recruits to the trial are currently being invited to take part in the study, and the first point at which we will see significant new evidence will be approximately three years after the trial begins. The PCUK website outlines the interim points over the course of the TRANSFORM trial when findings will be shared, with further information available at the following link:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 3 December 2024 to Question 5537 on Bowel Cancer: Screening, whether he expects bowel screening for 50 year-olds to be completed by (a) autumn or (b) winter 2025.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 3 December 2024 to Question 5537 on Bowel Cancer: Screening, whether he expects bowel screening for 50 year-olds to be completed by (a) autumn or (b) winter 2025.
The National Health Service in England has been gradually reducing the age for bowel screening from 60 years old down to 50 years old, since 2021/22. The extension to 50 years old is expected to be completed by 31 March 2025.
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of introducing bowel screening for people aged over 74.
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of introducing bowel screening for people aged over 74.
In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee, an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening, as well as supporting implementation.
As screening programmes can cause harms as well as benefits, each of the adult screening programmes has both an upper and lower age range within which there is good scientific evidence that the benefits of screening outweigh the harms.
The UK National Screening Committee does not currently recommend routine bowel screening over the age of 74 years old, as there is a lack of evidence regarding the harms and benefits of screening above this age. Once people are 75 years old or over, they can ask for a bowel screening kit every two years by phoning the free bowel cancer screening helpline on 0800 707 60 60.
That this House notes Cervical Cancer Prevention Week 2025, which takes place from 20 to 26 January; highlights that cervical screening is not easy for many, but screening is estimated to save 5,000 lives a year across the UK; underlines that this week is a chance to support and empower individuals to take control of their health, and that it is also a time to advocate for better access to resources and education around cervical health; further notes by working together as a community, people can break down stigmas, encourage conversations and make cervical cancer awareness and cancer prevention a priority; thanks the wonderful NHS for all they do to support women through cervical cancer prevention; and calls on the Government to support calls to review and lessen the age for commencement of cervical screening.
That this House notes Cervical Cancer Prevention Week 2025, which takes place from 20 to 26 January; highlights that cervical screening is not easy for many, but screening is estimated to save 5,000 lives a year across the UK; underlines that this week is a chance to support and empower...
To ask the Secretary of State for Health and Social Care, whether he plans to reduce the minimum age for bowel screening to 50 by the end of 2025.
To ask the Secretary of State for Health and Social Care, whether he plans to reduce the minimum age for bowel screening to 50 by the end of 2025.
NHS England is responsible for delivering the NHS Bowel Cancer Screening programme, including planning for the age extension in the programme from 60 down to 50 years old.
The age extension for bowel screening is already underway. NHS England started in April 2021 with the 56-year-old cohort and, based on modelling and clinical advice, has planned to gradually reduce to the age of 50 years old by 2025. This has been done to ensure that screening centres could manage any required increase in colonoscopy capacity.
That this House recognises the hard work of Stephen Rippington, who whilst battling against bowel cancer, was active in raising awareness for the disease both within his local area and online, and his wife Jessica who has raised over £10,000 for bowel cancer research; notes that 1 in 4 diagnoses occur among people aged under 50; and, following Stephen's passing earlier this year, calls for the age eligibility of screening tests for bowel cancer offered by the NHS to be reviewed.
That this House recognises the hard work of Stephen Rippington, who whilst battling against bowel cancer, was active in raising awareness for the disease both within his local area and online, and his wife Jessica who has raised over £10,000 for bowel cancer research; notes that 1 in 4 diagnoses...
To ask the Secretary of State for Health and Social Care, when his Department plans to offer bowel cancer screening to people aged 50.
To ask the Secretary of State for Health and Social Care, when his Department plans to offer bowel cancer screening to people aged 50.
The National Health Service in England has been gradually reducing the age for bowel screening from 60 years old down to 50 years old, since 2021/22. The extension to 50 years old is expected to be completed by 2025.